Herman Eisen resumes & CV records
Resumes
Herman N EisenCambridge, MA
Herman Eisen Phones & Addresses
Cambridge, MA
75 Cambridge Pkwy UNIT E806, Cambridge, MA 02142
Social networks
Herman N Eisen
Linkedin
Work
Position:
Construction and Extraction Occupations
Education
Degree:
Associate degree or higher
Mentions for Herman N Eisen
Publications & IP owners
Us Patents
In Vivo Ctl Elicitation By Heat Shock Protein Fusion Proteins Maps To A Discrete Domain And Is Cd4+ T Cell-Independent
US Patent:
6875435, Apr 5, 2005
Filed:
Jan 16, 2001
Appl. No.:
09/761534
Inventors:
Qian Huang - Arlington MA, US
Joan F. L. Richmond - Arlington MA, US
Bryan K. Cho - San Leandro CA, US
Deborah Palliser - Cambridge MA, US
Jianzhu Chen - Brookline MA, US
Herman N. Eisen - Waban MA, US
Richard A. Young - Weston MA, US
Joan F. L. Richmond - Arlington MA, US
Bryan K. Cho - San Leandro CA, US
Deborah Palliser - Cambridge MA, US
Jianzhu Chen - Brookline MA, US
Herman N. Eisen - Waban MA, US
Richard A. Young - Weston MA, US
Assignee:
Whitehead Institute for Biomedical Research - Cambridge MA
Massachusetts Institute of Technology - Cambridge MA
Massachusetts Institute of Technology - Cambridge MA
International Classification:
A61K039/00
A61K039/04
A61K039/385
A61K038/00
A61K038/04
A61K039/04
A61K039/385
A61K038/00
A61K038/04
US Classification:
4241901, 4241841, 4241851, 4241921, 4241931, 4241941, 42419711, 4242341, 4242461, 4242481, 4242011
Abstract:
The present invention relates to a method of inducing a CD8 CTL response to a molecule in an individual deficient in CD4 T cells comprising administering to the individual an hsp or a portion of an ATP binding domain of an hsp joined to the molecule. In one embodiment, the present invention relates to a method of treating HIV in an individual deficient in CD4 T cells comprising administering to the individual an hsp or a portion of an ATP binding domain of an hsp joined to the molecule. Also encompassed by the present invention is a method of inducing a CD4 independent CTL response in an individual comprising administering to the individual a portion of an ATP binding domain of an hsp joined to the molecule. The present invention also relates to a method of inducing a CD8 CTL response in an individual comprising administering to the individual a portion of an ATP binding domain of an hsp joined to the molecule. In addition, the present invention relates to a composition characterized by a portion of an ATP biding domain of an hsp joined to a molecule.
Vivo Ctl Elicitation By Heat Shock Protein Fusion Proteins Maps To A Discrete Domain And Is Cd4+ T Cell-Independent
US Patent:
7501125, Mar 10, 2009
Filed:
Jul 1, 2004
Appl. No.:
10/885523
Inventors:
Qian Huang - Arlington MA, US
Joan F. L. Richmond - Arlington MA, US
Bryan K. Cho - San Leandro CA, US
Deborah Pallister - Cambridge MA, US
Jianzhu Chen - Brookline MA, US
Herman N. Eisen - Waban MA, US
Richard A. Young - Weston MA, US
Joan F. L. Richmond - Arlington MA, US
Bryan K. Cho - San Leandro CA, US
Deborah Pallister - Cambridge MA, US
Jianzhu Chen - Brookline MA, US
Herman N. Eisen - Waban MA, US
Richard A. Young - Weston MA, US
Assignee:
Whitehead Institute for Biomedical Research - Cambridge MA
Massachusetts Institute of Technology - Cambridge MA
Massachusetts Institute of Technology - Cambridge MA
International Classification:
A61K 38/00
A61K 39/00
A61K 39/385
C07K 14/00
C07K 14/005
C07K 14/195
A61K 39/00
A61K 39/385
C07K 14/00
C07K 14/005
C07K 14/195
US Classification:
4241921, 4241841, 42419611, 42419711, 514 2, 530350, 530402, 530403
Abstract:
The present invention relates to a method of inducing a CD8 CTL response to a molecule in an individual deficient in CD4 T cells comprising administering to the individual an hsp or a portion of an ATP binding domain of an hsp joined to the molecule. In one embodiment, the present invention relates to a method of treating HIV in an individual deficient in CD4 T cells comprising administering to the individual an hsp or a portion of an ATP binding domain of an hsp joined to the molecule. Also encompassed by the present invention is a method of inducing a CD4 independent CTL response in an individual comprising administering to the individual a portion of an ATP binding domain of an hsp joined to the molecule. The present invention also relates to a method of inducing a CD8 CTL response in an individual comprising administering to the individual a portion of an ATP binding domain of an hsp joined to the molecule. In addition, the present invention relates to a composition characterized by a portion of an ATP biding domain of an hsp joined to a molecule.
Influenza Therapeutic
US Patent:
2004024, Dec 2, 2004
Filed:
Sep 29, 2003
Appl. No.:
10/674159
Inventors:
Jianzhu Chen - Brookline MA, US
Herman Eisen - Waban MA, US
Qing Ge - Cambridge MA, US
Herman Eisen - Waban MA, US
Qing Ge - Cambridge MA, US
Assignee:
Massachusetts Institute of Technology
International Classification:
A61K048/00
C07H021/02
C07H021/02
US Classification:
514/044000, 536/023100
Abstract:
The present invention provides methods and compositions for inhibiting influenza infection and/or replication based on the phenomenon of RNA interference (RNAi) well as systems for identifying effective siRNAs and shRNAs for inhibiting influenza virus and systems for studying influenza virus infective mechanisms. The invention also provides methods and compositions for inhibiting infection, pathogenicity and/or replication of other infectious agents, particularly those that infect cells that are directly accessible from outside the body, e.g., skin cells or mucosal cells. In addition, the invention provides compositions comprising an RNAi-inducing entity, e.g., an siRNA, shRNA, or RNAi-inducing vector targeted to an influenza virus transcript and any of a variety of delivery agents. The invention further includes methods of use of the compositions for treatment of influenza.
Compositions And Methods For Delivery Of Short Interfering Rna And Short Hairpin Rna
US Patent:
2005000, Jan 13, 2005
Filed:
Sep 29, 2003
Appl. No.:
10/674087
Inventors:
Jianzhu Chen - Brookline MA, US
Herman Eisen - Waban MA, US
Qing Ge - Cambridge MA, US
Herman Eisen - Waban MA, US
Qing Ge - Cambridge MA, US
International Classification:
A61K048/00
US Classification:
424093200, 514044000
Abstract:
The present invention provides compositions comprising an RNAi-inducing entity any of a variety of different delivery agents. Preferred RNAi-inducing agents include siRNA, shRNA, and RNAi-inducing vectors. Preferred delivery agents include cationic polymers, modified cationic polymers, lipids, and surfactants suitable for introduction into the lung. The invention further provides methods of inhibiting expression of a target transcript in a mammal and methods of treating or preventing a disease or condition in a mammal by administration of the compositions.
Rnai-Based Therapeutics For Allergic Rhinitis And Asthma
US Patent:
2006005, Mar 16, 2006
Filed:
Mar 1, 2005
Appl. No.:
11/069611
Inventors:
Jianzhu Chen - Brookline MA, US
Herman Eisen - Waban MA, US
Qing Ge - Cambridge MA, US
Herman Eisen - Waban MA, US
Qing Ge - Cambridge MA, US
International Classification:
A61K 48/00
C07H 21/02
C07H 21/02
US Classification:
514044000, 536023100
Abstract:
The present invention provides compositions comprising one or more RNAi agents (e.g., siRNAs, shRNAs, or RNAi vectors) for the treatment of conditions and diseases mediated by (e.g., featuring IgE-mediated hypersensitivity), as well as systems for identifying RNAi agents effective for this purpose. The compositions are suitable for the treatment of allergic rhinitis and/or asthma. In certain embodiments of the invention the RNAi agent is targeted to a transcript that encodes a protein selected from the group consisisting of the FCεRIα chain, the FCεRIβ chain, c-Kit, Lyn, Syk, ICOS, OX40L, CD40, CD80, CD86, Re1A, Re1B, 4-1BB ligand, TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, CD83, SLAM, common γ chain, and COX-2. In addition, the invention provides RNAi agent/delivery agent compositions and methods of use. In certain embodiments of the invention compositions comprising an RNAi agent are delivered by the respiratory route.
Influenza Therapeutic
US Patent:
2006016, Jul 20, 2006
Filed:
Apr 8, 2005
Appl. No.:
11/102097
Inventors:
Jianzhu Chen - Brookline MA, US
Qing Ge - Cambridge MA, US
Herman Eisen - Waban MA, US
Qing Ge - Cambridge MA, US
Herman Eisen - Waban MA, US
International Classification:
A61K 48/00
C12Q 1/70
C07H 21/02
C12Q 1/70
C07H 21/02
US Classification:
514044000, 435005000, 536023100
Abstract:
The present invention provides compositions comprising an RNAi-inducing entity targeted to an influenza virus transcript and any of a variety of delivery agents. The invention further includes methods of use of the compositions for inhibiting a biological activity of an influenza virus and/or for treatment or prevention of influenza. The invention provides target portion sequences that are favorably conserved for RNAi across a plurality of influenza virus A strains isolated from human hosts and/or avian hosts and RNAi-inducing entities, e.g., siRNAs and shRNAs, targeted to such favorably conserved target portions. The invention provides a variety of nucleic acids comprising sequences identical or complementary to at least a portion of one or more of these favorably conserved target portion sequences. The invention further provides methods and compositions for delivering RNAi-inducing agents to an organ or tissue of a mammalian subject, e.g., to the lung. Methods of diagnosing influenza and determining the susceptibility of an influenza virus to inhibition by an RNAi-inducing agent are also provided. Transgenic animals that express an RNAi-inducing agent targeted to an influenza gene are another aspect of the invention.
Influenza Therapeutic
US Patent:
2009010, Apr 23, 2009
Filed:
Dec 6, 2007
Appl. No.:
11/952056
Inventors:
Jianzhu Chen - Lexington MA, US
Herman N. Eisen - Waban MA, US
Qing Ge - Cambridge MA, US
Herman N. Eisen - Waban MA, US
Qing Ge - Cambridge MA, US
Assignee:
Massachusetts Institute of Technology - Cambridge MA
International Classification:
A01K 67/027
C07H 21/02
A61K 31/7105
A61K 9/12
A61P 31/16
C12N 15/63
C12N 5/10
C07H 21/02
A61K 31/7105
A61K 9/12
A61P 31/16
C12N 15/63
C12N 5/10
US Classification:
800 14, 536 245, 514 44, 536 231, 435325, 800 13, 4353201, 424 45
Abstract:
The present invention provides methods and compositions for inhibiting influenza infection and/or replication based on the phenomenon of RNA interference (RNAi) well as systems for identifying effective siRNAs and shRNAs for inhibiting influenza virus and systems for studying influenza virus infective mechanisms. The invention also provides methods and compositions for inhibiting infection, pathogenicity and/or replication of other infectious agents, particularly those that infect cells that are directly accessible from outside the body, e.g., skin cells or mucosal cells. In addition, the invention provides compositions comprising an RNAi-inducing entity, e.g., an siRNA, shRNA, or RNAi-inducing vector targeted to an influenza virus transcript and any of a variety of delivery agents. The invention further includes methods of use of the compositions for treatment of influenza.
Influenza Therapeutic
US Patent:
2009012, May 14, 2009
Filed:
Jul 3, 2008
Appl. No.:
12/167593
Inventors:
Jianzhu Chen - Lexington MA, US
Herman N. Eisen - Waban MA, US
Qing Ge - Cambridge MA, US
Herman N. Eisen - Waban MA, US
Qing Ge - Cambridge MA, US
International Classification:
A61K 31/7052
C07H 21/00
C12N 5/00
A61P 31/16
C12N 15/63
A01K 67/033
C07H 21/00
C12N 5/00
A61P 31/16
C12N 15/63
A01K 67/033
US Classification:
514 44, 536 231, 435325, 4353201, 800 13
Abstract:
The present invention provides methods and compositions for inhibiting influenza infection and/or replication based on the phenomenon of RNA interference (RNAi) well as systems for identifying effective siRNAs and shRNAs for inhibiting influenza virus and systems for studying influenza virus infective mechanisms. The invention also provides methods and compositions for inhibiting infection, pathogenicity and/or replication of other infectious agents, particularly those that infect cells that are directly accessible from outside the body, e.g., skin cells or mucosal cells. In addition, the invention provides compositions comprising an RNAi-inducing entity, e.g., an siRNA, shRNA, or RNAi-inducing vector targeted to an influenza virus transcript and any of a variety of delivery agents. The invention further includes methods of use of the compositions for treatment of influenza.
Isbn (Books And Publications)
Microbiology
Author:
Herman N Eisen
ISBN #:
0397506899
General Immunology
Author:
Herman N Eisen
ISBN #:
0397508336
Immunology
Author:
Herman N. Eisen
ISBN #:
0061407828
Cytotoxic Cells: Recognition, Effector Function, Generation, And Methods
Author:
Herman N. Eisen
ISBN #:
0817636080
Public records
Vehicle Records
Herman N Eisen
Address:
75 Cambridge Pkwy UNIT E806, Cambridge, MA 02142
Phone:
(617) 253-6406
VIN:
JTNBB46K673033222
Make:
TOYOTA
Model:
CAMRY HYBRID
Year:
2007
NOTICE: You may not use PeopleBackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. PeopleBackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.